Archive for September 2019

Why It’s Crucial to Monitor FDA Guidances

By Mark Land, AAHP President It can take several years for manufacturers to implement new guidelines from the Food and Drug Administration (FDA)—and that means they could be at risk in the meantime. However, manufacturers can “get ahead of the game” by monitoring FDA’s guidance development agenda. FDA’s authority to readm more…

Read More

Australia to Release the First Draft Report on Homeopathy Effectiveness

By Mark Land, AAHP President   Many believe the draft report arrived at a more encouraging conclusion regarding the effectiveness of homeopathy and may have been suppressed by the then conservative Australian government. After years of requests and inquiry, Australia’s National Health and Medical Research Council (NHMRC) has decided to readm more…

Read More

Alert: FDA Drug Listing Records Subject to Inactivation

By Eric Foxman, AAHP Secretary   Beginning September 14, 2019, and every January, FDA will begin to inactivate drug listings that are uncertified in the previous renewal period. Last month, the Food and Drug Administration (FDA) announced that it intends to inactivate drug listing records that are a) not certified readm more…

Read More